with @kristenfortney @laurademing @vijaypande @omnivorousread This is the very first episode in our new show, Bio Eats World, a brand new podcast all about how biology is technology: Bio is breaking out of the lab and clinic and into our daily lives -- on the verge of revolutionizing our world in ways we are only just beginning to imagine. In this first episode, we talk all about the science of aging. Be sure to subscribe (and rate if you like) this show, and to learn more about the expanding a16z Podcast network, please go to a16z.com/podnetwork
Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives -- on the verge of revolutionizing our world in ways we are only just beginning to imagine.
In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer’s -- and increasing the amount of time we are healthy -- today?
In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.
Be sure to subscribe to 'Bio Eats World' if you want to keep getting it (and please feel free to rate it as well). To learn more about the expanding a16z Podcast network, please visit a16z.com/podnetwork.